Psoriatic Arthritis - Pipeline Insight, 2021

This “Psoriatic arthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Psoriatic arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriatic arthritis Understanding

Psoriatic arthritis: Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.

"Psoriatic arthritis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic arthritis pipeline landscape is provided which includes the disease overview and Psoriatic arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic arthritis.

Psoriatic arthritis Emerging Drugs Chapters

This segment of the Psoriatic arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriatic arthritis Emerging Drugs

Tildrakizumab: Sun Pharma Global

Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. It is currently in preregistration stage for the treatment of psoriatic arthritis.

BMS-986165: Bristol-Myers Squibb

BMS-986165 (Deucravacitinib) is the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases. BMS-986165 selectivity is driven by a unique mechanism of action that is distinct from other kinase inhibitors. TYK2 is an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses. It is currently in phase 2 of development stage for the treatment of psoriatic arthritis.

AbGn-168H: AbGenomics

AbGn-168H is a humanized therapeutic antibody with a unique mechanism of action, which preferentially induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. It is currently in phase 2 of development stage for the treatment of psoriatic arthritis.

Apremilast: 3SBio

Apremilast is being developed by 3SBio for the treatment of psoriatic arthritis and is currently in Phase I of clinical trial study. Apremilast acts as Interleukin 23 inhibitors, tumour necrosis factor alpha inhibitors and type 4 cyclic nucleotide phosphodiesterase inhibitors.

Psoriatic arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriatic arthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Psoriatic arthritis

There are approx. 35+ key companies which are developing the therapies for Psoriatic arthritis. The companies which have their Psoriatic arthritis drug candidates in the most advanced stage, i.e. preregistration include, Sun Pharma Global.

Phases

This report covers around 35+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Psoriatic arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriatic arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriatic arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic arthritis drugs.

Psoriatic arthritis Report Insights

• Psoriatic arthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriatic arthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriatic arthritis drugs?
• How many Psoriatic arthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic arthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriatic arthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriatic arthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sun Pharma Global
• UCB Biopharma
• Pfizer
• Bristol-Myers Squibb
• AbGenomics
• Boehringer Ingelheim
• Affibody
• AltruBio
• Synact Pharma
• NeuClone
• 3SBio
• Qyuns Therapeutics
• Kangpu Biopharmaceuticals
• Alpine Immune Sciences
• Avotres
• Xbrane Biopharma
• XBiotech
• Evelo
• Luye Pharma Group
• Levolta Pharmaceuticals
• DNX Biopharmaceuticals
• Mycenax Biotech

Key Products

• Tildrakizumab
• Bimekizumab
• PF-06700841
• BMS-986165
• AbGn-168H
• BI 730357
• Izokibep
• Neihulizumab
• AP1189
• NeuLara
• Apremilast
• QX 002N
• KPG-612
• ALPN 101
• AVT001
• Xcimzane
• RHE 70202
• EDP1815
• DNX 514
• DNX 114